Coave Therapeutics

📍 Paris, France🗓 Founded 2014👥 41 employees💰 Last funded Jan 2025
Biotechnology Research🌐 coavetx.com
Website LinkedIn
Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
6
Total investors
1
Early stage
2
Mid stage
0
Late stage
2014
Founded

Investors

6 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
France
4
Belgium
1
Denmark
1
Investor activity2016–2025 · investors recorded per year
20161201712018120253
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Coave Therapeutics?
Coave Therapeutics has 6 investors on record on gritt.io, including 1 early-stage backers, 2 mid-stage.
When did Coave Therapeutics last raise funding?
The most recent investment in Coave Therapeutics recorded on gritt.io was in January 2025.
When was Coave Therapeutics founded?
Coave Therapeutics was founded in 2014.
What industry is Coave Therapeutics in?
Coave Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Coave Therapeutics based?
Coave Therapeutics is headquartered in Paris, France.